Literature DB >> 19025498

Clinical presentation of Mycoplasma genitalium Infection versus Neisseria gonorrhoeae infection among women with pelvic inflammatory disease.

Vanessa L Short1, Patricia A Totten, Roberta B Ness, Sabina G Astete, Sheryl F Kelsey, Catherine L Haggerty.   

Abstract

BACKGROUND: Women with pelvic inflammatory disease (PID) often present with a spectrum of symptoms. The characteristics of nongonococcal, nonchlamydial PID have not been well described. Our objective was to examine the characteristics of Mycoplasma genitalium infection among women with clinically suspected PID.
METHODS: We evaluated 722 women who were enrolled in the PID Evaluation and Clinical Health study. Women with M. genitalium monoinfection were compared with women with Neisseria gonorrhoeae monoinfection or Chlamydia trachomatis monoinfection.
RESULTS: Compared with women with gonococcal PID, women with M. genitalium infection were less likely to have elevated systemic inflammatory markers, including an erythrocyte sedimentation rate >15 mm/h (5 [22.7%] of 22 patients vs. 45 [60.8%] of 74 patients; P = .002), a white blood cell count >10,000 cells/mL (4 [28.6%] of 14 patients vs. 42 [64.6%] of 65 patients; (P = .018), and an oral temperature > or =38.3 degrees C (0 [0.0%] of 22 patients vs. 10 [13.9%] of 72 patients; (P = .001). In addition, they were less likely to present with mucopurulent cervicitis (9 [47.4%] of 19 patients vs. 60 [83.3%] of 72 patients; P = .001), elevated vaginal pH (P = .018), and high pelvic pain score (P = .014). In contrast, women with chlamydial PID had signs and symptoms that were similar to those in women with M. genitalium infection.
CONCLUSIONS: Because symptoms might be mild, women with M. genitalium infection might not seek PID treatment. Further studies are needed to assess the potential reproductive tract sequelae of M. genitalium infection of the upper genital tract.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19025498      PMCID: PMC2652068          DOI: 10.1086/594123

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  35 in total

1.  Association between Mycoplasma genitalium and acute endometritis.

Authors:  Craig R Cohen; Lisa E Manhart; Elizabeth A Bukusi; Sabina Astete; Robert C Brunham; King K Holmes; Samuel K Sinei; Job J Bwayo; Patricia A Totten
Journal:  Lancet       Date:  2002-03-02       Impact factor: 79.321

2.  High prevalence of Mycoplasma genitalium in the lower genitourinary tract of women attending a sexually transmitted disease clinic in Paris, France.

Authors:  Isabelle Casin; Dominique Vexiau-Robert; Pauline De La Salmonière; Aline Eche; Bernadette Grandry; Michel Janier
Journal:  Sex Transm Dis       Date:  2002-06       Impact factor: 2.830

3.  Tubal factor infertility: an association with prior chlamydial infection and asymptomatic salpingitis.

Authors:  J W Sellors; J B Mahony; M A Chernesky; D J Rath
Journal:  Fertil Steril       Date:  1988-03       Impact factor: 7.329

4.  Serological investigation of Mycoplasma genitalium in infertile women.

Authors:  H F Clausen; J Fedder; M Drasbek; P K Nielsen; B Toft; H J Ingerslev; S Birkelund; G Christiansen
Journal:  Hum Reprod       Date:  2001-09       Impact factor: 6.918

5.  Endometrial histopathology in patients with culture-proved upper genital tract infection and laparoscopically diagnosed acute salpingitis.

Authors:  N B Kiviat; P Wølner-Hanssen; D A Eschenbach; J N Wasserheit; J A Paavonen; T A Bell; C W Critchlow; W E Stamm; D E Moore; K K Holmes
Journal:  Am J Surg Pathol       Date:  1990-02       Impact factor: 6.394

6.  Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial.

Authors:  Roberta B Ness; David E Soper; Robert L Holley; Jeffrey Peipert; Hugh Randall; Richard L Sweet; Steven J Sondheimer; Susan L Hendrix; Antonio Amortegui; Giuliana Trucco; Thomas Songer; Judith R Lave; Sharon L Hillier; Debra C Bass; Sheryl F Kelsey
Journal:  Am J Obstet Gynecol       Date:  2002-05       Impact factor: 8.661

7.  Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation.

Authors:  R P Nugent; M A Krohn; S L Hillier
Journal:  J Clin Microbiol       Date:  1991-02       Impact factor: 5.948

8.  Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease.

Authors:  Harold C Wiesenfeld; Sharon L Hillier; Marijane A Krohn; Antonio J Amortegui; R Phillips Heine; Daniel V Landers; Richard L Sweet
Journal:  Obstet Gynecol       Date:  2002-09       Impact factor: 7.661

9.  Endometritis does not predict reproductive morbidity after pelvic inflammatory disease.

Authors:  Catherine L Haggerty; Roberta B Ness; Antonio Amortegui; Susan L Hendrix; Sharon L Hillier; Robert L Holley; Jeffrey Peipert; Hugh Randall; Steven J Sondheimer; David E Soper; Richard L Sweet; Guiliana Trucco
Journal:  Am J Obstet Gynecol       Date:  2003-01       Impact factor: 8.661

10.  Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results.

Authors:  L Weström; R Joesoef; G Reynolds; A Hagdu; S E Thompson
Journal:  Sex Transm Dis       Date:  1992 Jul-Aug       Impact factor: 2.830

View more
  24 in total

1.  Pelvic Inflammatory Disease: Current Concepts of Diagnosis and Management.

Authors:  Richard L Sweet
Journal:  Curr Infect Dis Rep       Date:  2012-02-02       Impact factor: 3.725

2.  Periodic Presumptive Treatment for Vaginal Infections May Reduce the Incidence of Sexually Transmitted Bacterial Infections.

Authors:  Jennifer E Balkus; Lisa E Manhart; Jeannette Lee; Omu Anzala; Joshua Kimani; Jane Schwebke; Juma Shafi; Charles Rivers; Emanuel Kabare; R Scott McClelland
Journal:  J Infect Dis       Date:  2016-02-04       Impact factor: 5.226

3.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

4.  Recurrent PID, subsequent STI, and reproductive health outcomes: findings from the PID evaluation and clinical health (PEACH) study.

Authors:  Maria Trent; Debra Bass; Roberta B Ness; Catherine Haggerty
Journal:  Sex Transm Dis       Date:  2011-09       Impact factor: 2.830

Review 5.  Mycoplasma genitalium: from Chrysalis to multicolored butterfly.

Authors:  David Taylor-Robinson; Jørgen Skov Jensen
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

Review 6.  Sexually transmitted diseases and infertility.

Authors:  Danielle G Tsevat; Harold C Wiesenfeld; Caitlin Parks; Jeffrey F Peipert
Journal:  Am J Obstet Gynecol       Date:  2017-01       Impact factor: 8.661

7.  Microbial correlates of delayed care for pelvic inflammatory disease.

Authors:  Brandie D Taylor; Roberta B Ness; Toni Darville; Catherine L Haggerty
Journal:  Sex Transm Dis       Date:  2011-05       Impact factor: 2.830

8.  RNA Biosignatures in Adolescent Patients in a Pediatric Emergency Department With Pelvic Inflammatory Disease.

Authors:  Fran Balamuth; Zhe Zhang; Eric Rappaport; Katie Hayes; Cynthia Mollen; Kathleen E Sullivan
Journal:  Pediatr Emerg Care       Date:  2015-07       Impact factor: 1.454

9.  Mycoplasma genitalium as a contributor to the multiple etiologies of cervicitis in women attending sexually transmitted disease clinics.

Authors:  Charlotte Gaydos; Nancy E Maldeis; Andrew Hardick; Justin Hardick; Thomas C Quinn
Journal:  Sex Transm Dis       Date:  2009-10       Impact factor: 2.830

10.  Recruitment of Minority Adolescents and Young Adults into Randomised Clinical Trials: Testing the Design of the Technology Enhanced Community Health Nursing (TECH-N) Pelvic Inflammatory Disease Trial.

Authors:  Maria Trent; Shang-En Chung; Charlotte Gaydos; Kevin D Frick; Jennifer Anders; Steven Huettner; Richard Rothman; Arlene Butz
Journal:  Eur Med J Reprod Health       Date:  2016-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.